Genovis AB (publ.) (GENO.ST)
- Previous Close
35.05 - Open
35.05 - Bid 34.65 x --
- Ask 34.85 x --
- Day's Range
34.10 - 35.05 - 52 Week Range
25.65 - 57.60 - Volume
18,419 - Avg. Volume
140,233 - Market Cap (intraday)
2.281B - Beta (5Y Monthly) 1.47
- PE Ratio (TTM)
75.76 - EPS (TTM)
0.46 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
51.50
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. In addition, the company offers GingisREX, a protease that digests proteins C-terminally of arginine residues; GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; and OpeRATOR, an O-glycan-specific protease. Further, it provides OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; GlycOCATCH, an affinity resin; GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a goat polyclonal antibody; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody. Additionally, the company offers antibodies, assay kits, reagents, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services, as well as operates an online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Europe, North America, and Asia. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.
www.genovis.comRecent News: GENO.ST
Performance Overview: GENO.ST
Trailing total returns as of 5/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GENO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GENO.ST
Valuation Measures
Market Cap
2.29B
Enterprise Value
2.25B
Trailing P/E
76.20
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.07
Price/Book (mrq)
11.18
Enterprise Value/Revenue
17.72
Enterprise Value/EBITDA
55.83
Financial Highlights
Profitability and Income Statement
Profit Margin
38.66%
Return on Assets (ttm)
15.61%
Return on Equity (ttm)
38.87%
Revenue (ttm)
159.07M
Net Income Avi to Common (ttm)
61.5M
Diluted EPS (ttm)
0.46
Balance Sheet and Cash Flow
Total Cash (mrq)
123.26M
Total Debt/Equity (mrq)
41.57%
Levered Free Cash Flow (ttm)
29.75M